Resmetirom Does More Than Treat Fatty Liver. It May…

Resmetirom Does More Than Treat Fatty Liver. It May Reshape the Entire Field. A new study suggests Resmetirom may do more than treat fatty liver disease. The thyroid hormone receptor beta agonist, approved in 2024 as the first drug specifically for metabolic dysfunction-associated steatohepatitis (MASH), is now showing effects that extend beyond liver histology improvement into broader metabolic and cardiovascular biomarker improvements. NPR MASH (formerly known as NASH) affe